A four-week Fodzyme study reported lower IBS symptom scores. Learn what changed, why the design matters and how to interpret the dietary implications.
On 2026-10-13, Medscape reported lower symptom scores after four weeks in adults with irritable bowel syndrome (IBS) using Fodzyme, a commercially available enzyme combination targeting selected fermentable carbohydrates. The study was led by Eden Koo, MD, of the University of Michigan and presented at the American College of Gastroenterology’s 2026 Annual Scientific Meeting.
The clinical starting point was continued evaluation rather than an established recommendation for this enzyme combination. Medscape’s coverage places the approach in that context: a candidate for further study rather than a proven replacement for existing IBS management. The announcement therefore adds evidence to an unsettled question rather than overturning an established enzyme treatment.
The study also began amid ongoing use of a low-FODMAP diet. Medscape and MedPage Today reported that 46.6% of participants were already following that approach at baseline. This places the enzyme findings alongside dietary management rather than in a setting where everyone entered with the same eating pattern.
A dietary approach and a targeted enzyme product raise different questions. One concerns food choices. The other concerns a combination designed to act on selected carbohydrates. Evidence about symptom changes during product use needs to be interpreted separately from evidence supporting a particular way of eating.
That distinction is useful when reading supplement coverage. Before asking whether a headline should change daily habits, it helps to identify the intended target and the outcome being measured. The related discussion of why the reason for using an enzyme matters provides context for reading these claims.
According to Medscape and MedPage Today, 442 participants completed assessments at baseline and after four weeks. The researchers used the IBS Symptom Severity Score, or IBS-SSS. This score brings together several dimensions of symptoms and their interference with daily life rather than measuring only one complaint.
Both outlets reported that mean IBS-SSS fell from 269.7 at baseline to 167.3 after four weeks. The mean paired decrease was 102.4 points. The reported comparison was statistically significant, with P<.001.
Medscape and MedPage Today also reported that 69.2% of participants had a reduction of at least 50 points. A reduction of at least 100 points was reported for 52.3% of participants. Koo described the four-week changes as clinically meaningful in Medscape’s coverage.
Those percentages refer to different thresholds for a change in the score. They are not percentages of symptom relief or measures of how much better an individual felt. Keeping the score and its thresholds separate makes the findings easier to interpret without turning them into a personal prediction.
The reports described changes across the IBS-SSS domains rather than only in the total score:
Medscape and MedPage Today reported these comparisons as statistically significant. The spread across domains gives the observation more detail than a headline about general improvement. The findings describe changes in pain and abdominal distension alongside bowel dissatisfaction and the effect of symptoms on everyday life.
These are related but distinct outcomes. A report about pain frequency answers a different question from a report about life interference. Presenting them separately helps show what the assessment captured rather than treating “IBS improvement” as a single experience shared by every participant.
The biological idea described in the reports is selective targeting of FODMAP carbohydrates. FODMAPs are fermentable carbohydrates relevant to the dietary approach discussed in this study. Medscape and MedPage Today described Fodzyme as targeting fructans, galacto-oligosaccharides and lactose.
That gives the research a specific focus. The question is about a named combination intended to act on selected carbohydrates rather than an unspecified aid to digestion. The reported symptom changes add a clinical observation to that targeted idea.
The immediate change is therefore in the research agenda. This combination now has an observed symptom pattern that warrants stronger testing. The announcement does not introduce a new dietary guideline or establish a new biological explanation for IBS.
MedPage Today reported a sensitivity analysis among participants already following a low-FODMAP diet. Symptom-score reductions were 101.1 points for participants in the personalization phase at baseline. They were 104.9 points for those who remained in the same phase through week four.
A sensitivity analysis is an additional look at the data under a more specific condition or grouping. Here it provided another view of symptom changes within the dietary context of the study. It also gives future research a focused question about how this enzyme approach fits alongside dietary management.
Medscape and MedPage Today described a prospective, single-arm observational study without randomization or blinding. There was no placebo or control group. Without that comparison, the before-and-after changes cannot show that the enzyme combination caused the improvement.
This is also where statistical significance needs context. A statistically significant change within the study group is not the same as proof of a treatment effect. The reports acknowledge that factors other than the supplement could account for the observed changes.
Follow-up lasted only four weeks, according to both reports. That leaves unanswered whether the symptom changes persist. It also leaves longer-term benefits and risks unresolved. The findings describe a short period of observation rather than the consequences of ongoing use.
MedPage Today noted possible selection bias because participants had proactively sought out the product. People who choose to obtain a particular supplement may differ from the wider population being considered for care. That feature matters when interpreting how broadly the observations apply.
The reports said the mean age was 50.3 and 86% of participants were women. Eligibility included self-reported IBS as well as physician-diagnosed IBS and/or Rome IV criteria. These features also limit how confidently the findings can be applied across different groups of adults with IBS.
The study evaluated one marketed combination. Its findings should not be transferred to enzyme supplements as a category or to products targeting other carbohydrates. The intended targets also do not cover all FODMAPs.
The reports did not establish that participants broadened their diets. Symptom-score changes and the ability to maintain a less restrictive eating pattern are different outcomes. A dietary benefit needs evidence of its own rather than being inferred from a lower symptom score.
Medscape’s coverage did not identify a peer-reviewed journal paper or provide an abstract number. The findings should be read as conference-reported evidence at this stage. That publication context is part of interpreting the announcement accurately.
Koo called for further evaluation in randomized, placebo-controlled trials, according to the reports. In Medscape’s coverage, UCLA gastroenterologist V. Raman Muthusamy described the findings as preliminary and hypothesis-generating. He said more evidence would be needed before recommending the approach in clinical practice.
For daily dietary choices, the realistic implication is patience rather than a new rule. This report is a reason to follow the research. It is not a reason for everyone with IBS to add a supplement or make an eating pattern more restrictive.
Personal decisions about recurring symptoms belong in a discussion with a qualified healthcare professional. The useful questions are about the person’s symptoms and circumstances rather than whether their experience resembles an average study score. A careful approach to describing symptom patterns can provide context for that conversation without turning an observation into a diagnosis.
Koo’s suggestion that the approach might eventually support less restrictive eating is a reasonable research goal. For now, the practical value of this announcement is a more focused question about food tolerance and targeted enzymes. It belongs in the evidence conversation rather than at the center of a new eating plan.
Turning the Fodzyme score changes into a personal food rule would skip the distinction between an observed result and advice suited to one adult. DigestGenius puts digestive research into clear context for questions about food and gut function. Its educational platform covers nutrition and microbiome science without presenting an emerging finding as a universal prescription.
DigestGenius publishes research-led guidance on digestion, the gut microbiome, fiber, probiotics, gut-brain signaling, inflammation and everyday digestive wellbeing.
Explore clear, research-led guidance on digestion, the microbiome, food, fiber, probiotics and the gut-brain connection.
read the blog
